Macrophage migration inhibitory factor (MIF) is a welldescribed proinflammatory mediator. MIF overexpression has been observed in many tumors and is implicated in oncogenic transformation and tumor progression. However, the molecular mechanisms responsible for regulating MIF expression remain poorly understood. In this study, we showed that the transcriptional repressor HBP1 (HMG box-containing protein 1) negatively regulates MIF expression. We first identified a large high-affinity HBP1 DNA-binding element at positions À811 to À792 from the transcriptional start site within the MIF promoter by computer analysis. Reporter analyses showed that this element was required for HBP1-mediated transcriptional repression. Furthermore, HBP1 associated with the MIF promoter in vivo and repressed endogenous MIF gene expression. Consistent with HBP1-mediated repression of MIF, low levels of HBP1 expression were associated with high levels of MIF expression in prostate cancer samples. Importantly, HBP1-mediated repression of MIF inhibited tumorigenic growth and invasion, and the repressive effect of HBP1 on tumorigenic growth and invasion could be partially rescued by the addition of recombinant MIF to the culture medium. Finally, prostate tumor samples with low HBP1 and high MIF expression were associated with a significant decrease in relapse-free survival. Taken together, these results indicated that HBP1 directly inhibited MIF gene transcription, and suggested that the loss of HBP1 expression or activity may contribute to the upregulation of MIF expression in prostate tumor tissue.
Introduction
HBP1 (HMG box-containing protein 1) is a transcriptional repressor and a member of the sequence-specific HMG box family of transcription factors. In addition to the HMG box-like sequence, which is the DNA-binding region, HBP1 contains two pocket protein-binding sequences: an LXCXE site and an IXCXE site. Human HBP1 also contains a 28 amino-acid sequence that shows 86% homology with a transcriptional activation domain previously identified in rat HBP1 (Lavender et al., 1997) ; the activation domain is flanked by two putative repressor domains. The presence of these sequences suggests that human HBP1 may activate and/or repress the transcription of other genes (Sampson et al., 2001) .
Mounting evidence suggests that HBP1 may function as a tumor suppressor. For example, HBP1 blocks the Wnt pathway , which is associated with diverse forms of epithelial cancer Liu et al., 2004; Reya and Clevers, 2005) . The HBP1 gene lies within the 7q31 chromosomal region that is frequently deleted or translocated in cancers (Lin et al., 2001) . Yee et al. (2004) have recently isolated variants of HBP1 in breast cancers and myeloid leukemia. Recently, HBP1 was shown to be required for oncogene-mediated premature senescence, which is a feature that is lost during malignant transformation (Zhang et al., 2006) . Thus, HBP1 exhibits many functional characteristics consistent with a role as a negative regulator of tumorigenesis.
Studies have shown that HBP1 has a key regulatory role in cell-cycle progression, cell-cycle exit, apoptosis and terminal differentiation in various tissues and cell types (Tevosian et al., 1997; Gartel et al., 1998; Shih et al., 1998; Lemercier et al., 2000) , consistent with a role in tumor suppression. HBP1 gene targets include N-Myc, c-Myc, cyclin D1, myeloperoxidase, histone H1 and p47phox (Lin et al., 2001; Sampson et al., 2001; Berasi et al., 2004) . Two underlying mechanisms for transcriptional inhibition by HBP1 have been described: (1) by direct binding to the target gene promoters and (2) by physically inhibiting the essential transcriptional activators.
Macrophage migration inhibitory factor (MIF) was one of the first cytokine mediators described. MIF is known as a widely expressed pleiotropic cytokine that modulates the activity of a broad range of inflammatory cytokines, overrides glucocorticoid-mediated immune suppression and regulates macrophage and lymphocyte function (Mitchell, 2004) . Recently, increasing evidence has shown that MIF has a key role not only in the immune response but also in tumor growth and progression. MIF overexpression has been identified in prostatic lymph node metastases, breast carcinoma, adenocarcinomas of the lung, bladder cancer and hepatocellular carcinomas (Meyer-Siegler et al., 1996; Bini et al., 1997; Shimizu et al., 1999; Kamimura et al., 2000; Ren et al., 2003; Meyer-Siegler et al., 2004) . A reduction in tumor-associated MIF expression resulted in decreased cell proliferation (Hudson et al., 1999) . Furthermore, MIF-deficient cells do not show enhanced proliferation after oncogenic transformation (Petrenko et al., 2003) . Taken together, these results suggest a role for MIF as an important cytokine involved in the regulation of tumor cell growth.
In a database search for high-affinity HBP1 sites, we found that the MIF promoter contains a predicted highaffinity HBP1-binding site located at positions À792 to À811 relative to the transcriptional start site. As previous studies have shown that HBP1 and MIF exert opposite effects with respect to tumor cell growth, we hypothesized that HBP1 may act as a transcriptional repressor of MIF. In this study, we showed that HBP1 inhibits MIF transcription, resulting in the inhibition of cell proliferation and reduced invasion of the DU-145 human prostate cancer cell line. The results of these experiments show that HBP1 and MIF expression levels show an inverse relationship that correlates with prostate cancer malignancy, and that HBP and MIF expression levels may be used to predict relapse. Our study establishes the MIF gene as a new target of the HBP1 transcriptional repressor and provides new mechanistic insights into HBP1-mediated inhibition of tumorigenesis.
Results

HBP1 represses MIF transcription in a DNA-bindingdependent manner
The HBP1 high-affinity binding site sequence (5 0 -TTCA TTCATTCA-3 0 ) was identified previously (Zhuma et al., 1999; Berasi et al., 2004) . In our searches, we identified an HBP1 high-affinity binding site in the MIF promoter ( Figure 1a ). We then carried out experiments using several reporter constructs to determine whether HBP1 could repress MIF transcription. To test the native MIF promoter, two reporter plasmids containing regions of the MIF promoter were generated: pGL3-1069 and pGL3-777. The pGL3-777 reporter construct lacks the predicted HBP1 high-affinity binding sites, whereas the pGL3-1069 reporter construct contains the predicted HBP1 high-affinity binding sites. DU-145 or RWPE2-W99 cell lines were cotransfected with one of the reporter vectors (pGL3-777 or pGL3-1069) together with the pRL-CMV vector as an internal control. At 36 h after transfection, the cells were harvested and analyzed for luciferase activity. As shown in Figure 1b , cells transfected with pGL3-1069, which contained the predicted highaffinity HBP1 sites, showed lower luciferase activity than did cells transfected with pGL3-777, which lacked the predicted HBP1-binding site; this difference was more evident in a prostate epithelial cell line (RWPE2-W99) than in a prostate cancer cell line (DU-145).
To determine whether RWPE2-W99 cells express higher levels of HBP1 than do DU-145 cells, which would lead to lower MIF expression and lower luciferase activity in cells transfected with pGL3-1069 as shown in Figure 1b , we examined HBP1 and MIF protein expression levels in immunoblot experiments. As shown in Figure 1c , RWPE2-W99 cells expressed higher levels of HBP1 and significantly lower levels of MIF than did DU-145 cells, suggesting a link between HBP1 and MIF expression.
To determine whether HBP1 repressed transcription from the MIF promoter, DU-145 cells were cotransfected with a vector for expression of HA-tagged HBP1 and either the pGL3-1069 reporter plasmid or the HBP1-specific 4XJ reporter gene as a positive control. As shown in Figure 1d , the expression of wild-type HBP1 resulted in efficient transcriptional repression of both the pGL3-1069 and the HBP1-specific 4XJ reporters in DU-145 cells; this effect was not seen in cells cotransfected with HA-tagged HBP1 and the pGL3-777 reporter, which lacks the predicted highaffinity HBP1-binding site.
To further confirm that HBP1 repressed transcription from the MIF prompter, RWPE2-W99 cells were transfected with a vector for short hairpin RNA (shRNA)-mediated HBP1 silencing together with the pGL3-Basic, pGL3-777 or pGL3-1069 vector. As shown in Figure 1e , RWPE2-W99 cells transfected with pGL3-1069, in which HBP1 expression was subjected to shRNA-mediated silencing, exhibited lower luciferase activity than did RWPE2-W99 cells transfected with pGL3-1069. Such a decrease in luciferase activity was not seen in RWPE2-W99 cells transfected with the pGL3-777 reporter or the negative control vector pGL3-Basic in which HBP1 was subjected to shRNA-mediated silencing. Immunoblot analysis confirmed efficient shRNA-mediated targeting of HBP1 in RWPE2-W99 cells (Figure 1f ).
To further confirm that the HBP1-binding site is indeed responsible for transcriptional repression of HBP1 represses MIF transcription YC Chen et al MIF, we used site-directed mutagenesis to modify three different randomly selected base pairs within the HBP1-binding site in the pGL3-1069 reporter gene ( Figure 1a ). We cotransfected DU-145 cells with a vector for expression of HA-tagged HBP1 or with an empty control vector together with the mutated pGL3-1069 reporter vectors and measured luciferase activity after normalization to the pRL-CMV control. As shown in Figure 1g , all three of the mutant pGL3-1069 vectors failed to exhibit HBP1-mediated transcriptional repression relative to the wild-type control. These data indicate that the predicted high-affinity HBP1 DNAbinding site in the MIF promoter did confer transcriptional repression. Using selected HBP1 mutants (Figure 2a ), we tested the requirement for HBP1 DNA-binding and repression domains with respect to transcriptional inhibition of MIF. To determine whether the HBP1 DNA-binding domain is required for transcriptional inhibition of MIF, we expressed HBP1 with a mutated HMG box (designated pmHMG) in DU-145 cells. As shown in Figure 2b , the pmHMG mutant failed to repress either the pGL3-1069 reporter or the 4XJ reporter, both of which contain the high-affinity HBP1-binding site. Therefore, repression of the MIF promoter by HBP1 requires HMG box-mediated DNA-binding activity. It has been reported previously that amino-acid residues 220-414 of HBP1 correspond to the transcriptional repression domain. Deletion of HBP1 amino-acid residues 218-314 (D218-314) abolished its ability to repress either the pGL3-1069 reporter or the 4XJ reporter ( Figure 2b ; wild-type HBP1 versus D218-314). Expression of the negative control reporters, pGL3-777 or pGL3-Basic, was not affected by either wild-type HBP1 or D218-314 HBP1. Therefore, HBP1-mediated transcriptional repression of MIF required both the DNA-binding domain and the repression domain of HBP1. Representative anti-HA immunoblots are shown in Figure 2c , showing that the HBP1 mutants used in Figure 2b were expressed at levels similar to those of wild-type HBP1.
HBP1 represses endogenous MIF transcription
We next determined whether HBP1 could bind to and repress transcription from the endogenous MIF promoter. Binding of HBP1 to the endogenous MIF promoter was determined by ChIP (chromatin immunoprecipitation) assays. HBP1 overexpressed in DU-145 cells bound to the endogenous MIF promoter in the region of the HBP1 high-affinity sites (Figure 3a , upper panel, lane 2). In contrast, pmHMG, which is defective in DNA binding, did not bind to the endogenous MIF promoter (Figure 3a , upper panel, lane 1). As a negative control, PCR amplification of the promoter region from À1930 to À1754, which lacks the HBP1 high-affinity EMSA experiments were performed using a radiolabeled double-stranded DNA probe consisting of a single HBP1 high-affinity binding site. A total of 50 mg of nuclear DNA extracts from DU-145 cells transfected with a vector for HBP1 overexpression, DU-145 cells transfected with the pmHMG expression plasmid, RWPE2-W99 cells and DU-145 cells were used. Experiments using nuclear extracts from these cells are designated 'H,' 'pm,' 'R' and 'D,' respectively. Cold competitor probes were included in the indicated lanes at 100-fold excess. The presence of specific complexes is indicated with arrows.
site, did not yield a signal (lower panel). Representative anti-HA immunoblots showed that both wild-type and pmHMG HBP1 were expressed (Figure 3b ). Furthermore, endogenous HBP1 also bound to the high-affinity site in the MIF promoter region in RWPE2-W99 cells (Figure 3c) . Collectively, these results show that HBP1 can bind specifically to the endogenous MIF promoter.
Electrophoretic mobility shift assay (EMSA) experiments provided an independent demonstration that HBP1 binds specifically to the high-affinity site in MIF. The results of these experiments showed the formation of a specific DNA/protein complex formed between transfected wild-type HBP1 and the predicted HBP1-binding site in the MIF promoter (Figure 3d ; lanes 2 and 5), whereas the pmHMG HBP1 mutant, which lacked the HMG DNA-binding domain, failed to interact with the MIF promoter (Figure 3d ; lane 4). The specificity of the DNA/protein complex was confirmed by incubation with a 100-fold excess of unlabeled probe, which competed with the labeled probe ( Figure 3d ; lane 3). Furthermore, the complex did not form when anti-HBP1 antibody was included in the binding reaction (Figure 3d ; lane 6), whereas incubation with the negative control anti-Foxo3a antibody did not disrupt complex formation (Figure 3d ; lane 7).
To determine whether endogenous HBP1 also binds to the high-affinity site, RWPE2-W99 and DU-145 nuclear extracts were used in EMSA experiments. The results of these experiments showed that a DNA/protein complex was observed when the labeled probe was incubated with RWPE2-W99 nuclear extracts (Figure 3d ; lane 9), whereas no complex was found using nuclear extracts from DU-145 cells, which exhibited very low levels of HBP1 expression (Figure 3d ; lane 8). The specificity of the DNA/protein complex was confirmed by incubation with a 100-fold excess of unlabeled probe, which competed with the labeled probe (Figure 3d; lanes 11 and 12) . Taken together, the results of the EMSA and ChIP experiments showed that HBP1 binds to the predicted high-affinity binding element in the MIF promoter.
On the basis of the ability of HBP1 to bind to the endogenous MIF promoter, we investigated the impact of HBP1 expression on endogenous MIF mRNA expression in DU-145 cells. Relative MIF mRNA levels were determined by semi-quantitative reverse transcriptase-PCR using GAPDH (glyceraldehyde 3-phosphate dehydrogenase) mRNA as an internal control. DU-145 cells expressing HBP1 showed significantly lower levels of MIF mRNA relative to DU-145 cells expressing pmHMG or the pBabe control vector (Figure 4a ). As a positive control, N-Myc gene expression was effectively inhibited by HBP1, but not by the expression of pmHMG or the pBabe control vector (Figure 4a ). To determine whether HBP1-mediated changes in endogenous MIF mRNA expression also resulted in decreased MIF protein expression, we carried out immunoblot analyses using an anti-MIF polyclonal antibody. Expression of HBP1, but not pmHMG or the pBabe control vector, inhibited MIF protein expression (Figure 4b ).
To further confirm that HBP1 negatively regulates MIF expression, we used retroviral shRNA strategies to knock down HBP1 protein levels and to assess MIF expression in RWPE2-W99 cells. As shown in Figure 4c , HBP1 protein levels were stably knocked down, and this effect was also observed at the mRNA level (data not shown). HBP1 shRNA-mediated silencing was associated with an increase in MIF expression. This result is in agreement with the ability of HBP1 to bind to the MIF promoter and inhibit MIF transcription, and shows that HBP1 inhibits endogenous MIF protein expression.
HBP1-mediated inhibition of MIF expression is negatively correlated with prostate cancer To determine whether HBP1-mediated inhibition of MIF expression is associated with tumor growth, we carried out experiments to test whether HBP1 expression correlated negatively with MIF expression in prostate tumor tissues. We used real-time PCR to measure HBP1 and MIF mRNA levels in prostate cancer and normal prostate tissue. As shown in Figure 4d , 18 out of 22 prostate cancer tissue samples showed reduced HBP1 mRNA levels, whereas elevated MIF mRNA levels were detected in 21 cancer tissue samples. We used Pearson's correlation analysis to analyze the correlation between HBP1 and MIF. The results indicated an inverse correlation between HBP1 expression and MIF expression and were significant (Supplementary Figure 1A) . The primary data are supplied as an Excel file in Supplementary Table 1. These findings showed that HBP1 expression correlated negatively with MIF expression in prostate cancer tissue samples. In particular, low levels of HBP1 expression combined with high levels of MIF expression were associated with prostate cancer. To independently confirm the results of these experiments, we analyzed the correlation between HBP1 and MIF expression in normal and tumor prostate tissue samples from Oncomine (Catherine, MS, USA), and a similar inverse correlation between HBP1 and MIF expression in the prostate tumor tissue samples was observed (Supplementary Figure 1B) . The primary data are supplied as an Excel file in Supplementary Table 2 .
We next determined whether a combination of low HBP1 and high MIF expression correlated with prostate cancer pathology scores in prostate cancer specimens. According to Gleason's grading system, these specimens were divided into two groups: 6 specimens (S5, S7, S9, S16, S20 and S22) with a Gleason score of 6, and 16 specimens with a Gleason score of 7. All 16 specimens with a Gleason score of 7 had low HBP1 and high MIF expression, except 1 sample (S12). In contrast, of the six specimens with a Gleason score of 6, three cases (S5, S9 and S16) did not show such a correlation (Figure 4e ). Fisher's exact test showed that the two-sided P-value was 0.045 (o0.05), suggesting that the specimens with a Gleason score of 7 were more likely to show a pattern of low HBP1 and high MIF expression than were those with a Gleason score of 6.
HBP1-mediated repression of MIF expression contributes to tumor cell proliferation and invasion
Next, we determined whether HBP1-mediated repression of MIF modulates tumorigenic growth and invasion. First, MTT assays were used to examine cell growth. DU-145 cells overexpressing HBP1 grew slower than did pBabe-transfected control cells (Figure 5a ).
However, the addition of recombinant MIF (rMIF) to the culture medium partly restored proliferation in HBP1-overexpressing cells. Consistent with this result, the RWPE2-W99 cells with shRNA-mediated inhibition of HBP1 expression grew faster than did control cells (Figure 5b ). In agreement with the results from the MTT assay, HBP1-overexpressing DU145 cells showed a decreased ability to form colonies in soft agar relative to pBabe-transfected control cells. However, when HBP1-overexpressing cells were cultured in the presence of rMIF, the number of colonies increased (Figure 5c ).
Matrigel invasion assays of HBP1-overexpressing DU-145 cells also showed decreased invasion (Figure 5d ), which was reversed by the addition of rMIF (100 ng/ml) to the upper transwell chamber. These results showed that: (1) HBP1 expression may inhibit cancer cell growth and invasion, consistent with previous reports; and (2) the repression of MIF expression may contribute to HBP1-mediated effects on cancer cell growth and invasion.
Low HBP1 and high MIF expression are associated with prostate cancer relapse Finally, we determined whether the expression levels of HBP1 and MIF correlated with prostate cancer outcomes. When the relapse potential associated with low HBP1 and high MIF expression was considered, there was a significant decrease in relapse-free survival for patients with prostate tumors who had low HBP1 and high MIF expression (P ¼ 0.003; Supplementary Figure  2 ; Supplementary Table 1). In Supplementary Figure 2 , the Kaplan-Meier survival analysis showed that the median relapse-free time after therapy of patients in the group with low HBP1 and high MIF expression was 15.0 months, whereas the median relapse-free time after therapy of patients in the group with high HBP1 and low MIF expression was 33.0 months. Overall, 70% of patients in the group with low HBP1 and high MIF expression recurred within 2 years after therapy, whereas all patients in the group with high HBP1 and low MIF expression remained relapse free for at least 2 years. Thus, prostate tumors with low HBP1 and high MIF expression statistically predicted relapse, providing a two-gene criterion to investigate in future prognostic studies.
Discussion
In this study, we showed that HBP1 inhibited MIF expression in a manner that required both the HBP1 DNA-binding domain and the HBP1 repression domain. On the basis of our findings, we conclude that MIF is a direct target gene of HBP1. This conclusion is supported by the following results: (1) computer analysis identified a long HBP1 high-affinity binding site in the MIF promoter; (2) reporter constructs lacking the predicted HBP1-binding site or with a mutated HBP1-binding site did not exhibit HBP1-mediated repression; (3) HBP1 bound to the predicted HBP1-binding site in the MIF promoter and inhibited endogenous MIF expression; (4) mutations within the HBP1-binding site prevented its ability to inhibit MIF expression; (5) HBP1 expression correlated negatively with MIF expression in prostate tumor samples; and (6) the repressive effect of HBP1 on cancer cell growth and invasion could be partially rescued by the addition of rMIF to the culture medium.
Although some reports have suggested that HBP1 may function as a transcriptional activator, HBP1-mediated repression of cancer was attributed to its inhibitory effects on target genes (Lin et al., 2001) . For example, HBP1 transcriptionally inhibits the expression of the proto-oncogene N-Myc, which is associated with tumor progression. In addition, HBP1 is a negative regulator of the Wnt pathway, which is implicated in breast and other cancers. Our study showed that HBP1 expression may inhibit cell proliferation, colony formation and invasion, and that these effects were partially dependent on HBP1-mediated repression of MIF expression. The identification of MIF as an inhibitory target of HBP1 expands our mechanistic understanding of HBP1-mediated regulation of tumor cell proliferation and invasion.
Compelling evidence shows that MIF overexpression is associated with and contributes to the pathology of inflammatory and malignant diseases. However, the underlying molecular mechanisms that contribute to MIF overexpression have not been elucidated. Previous studies have shown a role of reduced HBP1 expression in breast cancer. In this study, we found that HBP1 expression levels are reduced in prostate cancer in comparison with normal controls, and that increased expression of HBP1 in the DU-145 human prostate cancer cell line resulted in decreased proliferation and invasion, suggesting that reduced HBP1 expression may also contribute to prostate cancer. In addition, analysis of the correlation between HBP1 and MIF expression with prostate cancer Gleason score in prostate specimens showed that specimens with a Gleason score of 7 were more likely to show a pattern of low HBP1 and high MIF expression than were those with a Gleason score of 6. The Gleason score is a very important factor for predicting prostate cancer invasion and metastasis (Walsh, 2002) . Therefore, this result suggests that patients with prostate cancer specimens that exhibit low HBP1 and high MIF expression may be assigned a poor prognosis. Additional clinical data will be required to confirm the association between HBP1 expression, MIF expression and prostate cancer prognosis.
Materials and methods
The detail of these experiments can be found in Supplementary materials.
Database searches
The HBP1 high-affinity DNA-binding site sequence (5 0 -TTC ATTCATTCA-3 0 , Zhuma et al., 1999) was used to query the Regulatory Sequence Analysis Tools using the Genome Scale Pattern Matching program (http://rsat.ulb.ac.be/rsat/). The results of this analysis showed that the MIF gene promoter contains a large HBP1-binding site at positions À811 to À792 relative to the transcriptional start site (see Figure 1a) .
Cell culture RWPE2-W99 cell lines (prostate epithelial cell lines) and DU-145 cell lines (prostate carcinoma cell lines) were purchased from the American Type Culture Collection (Manassas, VA, USA). Phoenix packaging cells (Orbigen Inc., San Diego, CA, USA) were a kind gift from Dr Amy S Yee.
Prostate samples A total of 17 pairs of tissue samples (S1-S17) from 17 patients were obtained from a tissue bank at the Institute of Urology (Peking University, China). An additional five pairs of tissue samples (S18-S22) from five patients were obtained from the Department of Urology, Sir Run Run Shaw Hospital. These tissue samples were operative samples of radical prostatectomy and were diagnosed by pathology. All tumor specimens were graded by Gleason's grading system. The Gleason score of 6 of the tumor specimens was 6(3 þ 3), and the Gleason score of 16 tumor specimens was 7(3 þ 4 or 4 þ 3); the details of the specimens are presented in Supplementary Table 1. Every pair of samples included one prostate carcinoma tissue sample and one normal prostate tissue sample.
Construction of reporter vectors and luciferase assays
The 1069 and 777 bp human MIF promoter regions were amplified by PCR and cloned into the pGL3-Basic vector (Promega Corporation, Madison, WI, USA). The resulting plasmids containing the 1069 and 777 bp MIF promoter regions were designated pGL3-1069 and pGL3-777, respectively. The PCR primers used to amplify the promoter regions are shown in Table 1 . Point mutations in the HBP1-binding site were introduced using the Quick-Change site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) and the pGL3-1069 vector was used as template. The primers and mutated bases are shown in Table 1 . Resulting mutants were designated as pGL3-mut1, pGL3-mut2 and pGL3-mut3, respectively. To directly attribute repression to the HBP1-binding sites, four adjacent high-affinity HBP1 sites (5 0 -TTCATTCATTCA-3 0 ) were inserted upstream of a CMV promoter (pGL3-4XJ) to test for repression. Luciferase activity was determined using the Dual-Luciferase Reporter Assay System Kit (Promega Corporation).
Vectors for retroviral-mediated gene expression
The pBabe, HBP1, pmHMG and D218-314 expression vectors were a kind gift from Dr Amy S Yee . Retroviral gene transduction was carried out using Phoenix packaging cells.
ChIP assays
ChIP assays were performed as described in the study by Shang et al. (2002) . The PCR primer set specific to the HBP1-binding sequence within the MIF promoter region and the control PCR primer set is shown in Table 1 .
Electrophoretic mobility shift assays EMSA experiments were performed as described previously (Lu et al., 2005) . A double-stranded oligonucleotide probe (5 0 -CCCATTCATTCATTCATTCATTCAGCAG-3 0 ) corresponding to bases À815 to À788 in the MIF promoter was used, which encompasses the HBP1-binding site. Anti-HBP1 antibody was used in super-shift reactions with anti-Foxo3a antibody as a negative control.
HBP1 knockdown
RNAi-mediated HBP1 knockdown was accomplished by shRNA produced by the DNA-based shRNA-expressing retroviral vector (pSuper-Retro). The vectors were a kind gift from Dr Amy S Yee. The knockdown experiment was performed as described previously (Paulson et al., 2007) . The HBP1 shRNA target sequence is ACTGTGAGTGCCACTTCTC.
Reverse transcriptase-PCR and real-time PCR RNA from cultured cells was isolated using a Qiagen RNeasy Kit (Qiagen, Valencia, CA, USA). RNA from tissues was isolated using TRIzol reagent (Invitrogen Corporation, Carlsbad, CA ,USA ). The primers used in reverse transcriptase-PCR are shown in Table 1 .
Real-time reverse transcriptase-PCR was performed using an Applied Biosystems 7300 Fast Real-time PCR System (Applied Biosystems, Foster City, CA, USA) using the real-time PCR Master Mix (Toyobo, Osaka, Japan). The primer sequences for real-time PCR of HBP1, MIF and GAPDH are shown in Table 1 .
Protein lysate preparation and immunoblot analysis
Whole cell lysates from cultured cells were prepared by homogenization in a lysis buffer containing phosphatase and protease inhibitors. The samples were separated on 15% SDSpolyacrylamide gels. Anti-HBP1 polyclonal antibody (sc-8488, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-MIF polyclonal antibody (sc-20121, Santa Cruz Biotechnology) or anti-actin polyclonal antibody (sc-1616-R, Santa Cruz Biotechnology) was used as the primary antibody.
MTT assays Cells were plated in 96-well dishes and cultured under normal conditions. Purified recombinant human MIF (rMIF No. 289-MF R&D Systems, Minneapolis, MN, USA) was added to the HBP1-transfected DU-145 cell culture media. MTT assays used 50 ml MTT (Promega Corporation) per well. The absorbance at 490 nm was determined using an automated microplate reader (Bio-Rad, Hercules, CA, USA).
Colony formation assays
For colony formation assays, cells were suspended in Dulbecco's modified Eagle's medium containing fetal bovine serum and plated in 6-well dishes with an agar bottom layer. The cells were cultured at 37 1C and rMIF (100 ng/ml) was added to the HBP1-transfected DU-145 cell culture media. After 14 days, the colonies were stained using crystal violet and counted microscopically within the field of a Â 40 objective lens (Nikon Eclipse TE 2000-U, Nikon, Tokyo, Japan).
Matrigel invasion assays
Matrigel invasion assays were conducted in 24-well transwell culture plates containing microporous membranes coated with Matrigel (BD Biosciences, San Jose, CA, USA) diluted 1:3 with Dulbecco's modified Eagle's medium. Cells were added to the upper chamber containing basal medium; rMIF was added to the upper chamber containing HBP1-transfected DU-145 cells. The lower chambers contained Dulbecco's modified Eagle's medium with fetal bovine serum. After a 36 -h incubation, the number of adherent cells on the lower surface of the insert was counted in nine representative fields at a Â 100 magnification (Nikon Eclipse TE 2000-U).
Statistical analysis
For the correlations of HBP1 and MIF, the Oncomine was used to compile a data file with Oncomine-normalized HBP1 and MIF mRNA expression levels for each patient. SPSS 13.0 (SPSS Inc., Chicago, IL, USA) was used for data analysis throughout this article. A level of 0.05 was used to determine statistical significance when interpreting results.
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